Skip to main content
SpringerLink
Log in

HIV-1 Entry Inhibitor Resistance

  • Living reference work entry
  • First Online:
Handbook of Antimicrobial Resistance

  • 162 Accesses

Abstract

Purpose of review: This review discusses resistance to HIV entry inhibitors with a focus on currently approved drugs and future uses.

Recent findings: The HIV entry inhibitor class is unique among HIV antiretrovirals as it encompasses drugs that target the different stages of the HIV entry cascade. There are currently 2 FDA-approved drugs in this class, the chemokine receptor-5 (CCR5) antagonist maraviroc (MVC) and the fusion inhibitor enfuvirtide (T-20). Attachment inhibitors are still under development, with multiple candidates in various states of development. Coreceptor antagonists are the most widely studied because patients who lack CCR5 are protected from HIV infection. CXCR4-antagonist development has proceeded more cautiously, due to limited antiviral effect in clinical trials. Fusion inhibitor development is advancing slowly, with the majority of research focusing on orally available small-molecule inhibitors. Resistance to these subclasses manifests in a complex manner and does not conform to the resistance paradigm of other antiretroviral classes.

Summary: This review will describe this heterogeneous class of antiretrovirals and the unique challenges and opportunities that they present in the pursuit of improving options for treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Allers K, Hütter G, Hofmann J et al (2011) Evidence for the cure of HIV infection by Ccr5{delta}32/{δ}32 stem cell transplantation. Blood 117:2791–2799

    Google Scholar 

  • Alonzo F 3rd, Kozhaya L, Rawlings SA et al (2013) Ccr5 is a receptor for Staphylococcus aureus leukotoxin Ed. Nature 493(7430):51–55, Epub 14 Dec 2012

    PubMed  Google Scholar 

  • Araujo LA, Junqueira DM, de Medeiros RM et al (2012) Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and Crf31_Bc. J Clin Virol 54(1):6–10, Epub 18 Feb 2012

    CAS  PubMed  Google Scholar 

  • Armand-Ugon M, Quinones-Mateu ME, Gutierez A et al (2003) Reduced fitness of HIV-1 resistant to Cxcr4 antagonists. Antivir Ther 8(1):1–8, Epub 26 Apr 2003

    CAS  PubMed  Google Scholar 

  • Baba M, Takashima K, Miyake H et al (2005) Tak-652 inhibits Ccr5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother 49(11):4584–4591, Epub 28 Oct 2005

    PubMed Central  CAS  PubMed  Google Scholar 

  • Baba M, Miyake H, Wang X et al (2007) Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule Ccr5 antagonist Tak-652. Antimicrob Agents Chemother 51(2):707–715, Epub 23 Nov 2006

    PubMed Central  CAS  PubMed  Google Scholar 

  • Baldwin C, Berkhout B (2008) Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant. J Virol 82(15):7735–7740, Epub 16 May 2008

    PubMed Central  CAS  PubMed  Google Scholar 

  • Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17:657–700, Epub 08 Jun 1999

    CAS  PubMed  Google Scholar 

  • Brumme ZL, Goodrich J, Mayer HB et al (2005) Molecular and clinical epidemiology of Cxcr4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 192(3):466–474, Epub 05 July 2005

    CAS  PubMed  Google Scholar 

  • Burkly LC, Olson D, Shapiro R et al (1992) Inhibition of HIV infection by a novel Cd4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 149(5):1779–1787, Epub 01 Sept 1992

    CAS  PubMed  Google Scholar 

  • Carmona R, Perez-Alvarez L, Munoz M et al (2005) Natural resistance-associated mutations to enfuvirtide (T20) and polymorphisms in the Gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol 32(3):248–253, Epub 22 Feb 2005

    CAS  PubMed  Google Scholar 

  • Ceccherini-Silberstein F, Alteri C, Surdo M et al (eds) (2011) HIV-1 dual/mixed-tropic viruses can be inhibited in vitro as in vivo by Maraviroc: a refined analysis from patients enrolled in the phase-Iib study-A4001029. In: IAS 2011, Rome

    Google Scholar 

  • Cecilia D, Kulkarni SS, Tripathy SP et al (2000) Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology 271(2):253–258, Epub 22 Jun 2000

    CAS  PubMed  Google Scholar 

  • Chambers P, Pringle CR, Easton AJ (1990) Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J Gen Virol 71(Pt 12):3075–3080, Epub 01 Dec 1990

    CAS  PubMed  Google Scholar 

  • Chang CH, Hinkula J, Loo M et al (2012) A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro. PLoS One 7(7):e41235, Epub 31 July 2012

    PubMed Central  CAS  PubMed  Google Scholar 

  • Charpentier C, Larrouy L, Visseaux B et al (2012) Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor Bms-626529 in HIV-1 ‘Non-B ’-infected patients. J Antimicrob Chemother 67(6):1459–1461, Epub 03 Mar 2012

    Google Scholar 

  • Chen B, Vogan EM, Gong H et al (2005) Structure of an unliganded simian immunodeficiency virus Gp120 core. Nature 433(7028):834–841, Epub 25 Feb 2005

    CAS  PubMed  Google Scholar 

  • Coetzer M, Nedellec R, Cilliers T et al (2011) Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr 56(1):9–15, Epub 06 Oct 2010

    PubMed Central  PubMed  Google Scholar 

  • Connor RI, Sheridan KE, Ceradini D et al (1997) Change in coreceptor use correlates with disease progression in HIV-1–infected individuals. J Exp Med 185(4):621–628, Epub 17 Feb 1997

    PubMed Central  CAS  PubMed  Google Scholar 

  • Cooper DA, Heera J, Goodrich J et al (2010) Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with Ccr5-tropic HIV-1 infection. J Infect Dis 201(6):803–813

    CAS  PubMed  Google Scholar 

  • Covens K, Kabeya K, Schrooten Y et al (2009) Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes. J Clin Virol 44(4):325–328, Epub 25 Feb 2009

    CAS  PubMed  Google Scholar 

  • Daar ES, Li XL, Moudgil T et al (1990) High concentrations of recombinant soluble Cd4 Are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A 87(17):6574–6578, Epub 01 Sept 1990

    PubMed Central  CAS  PubMed  Google Scholar 

  • De Jong JJ, De Ronde A, Keulen W et al (1992) Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66(11):6777–6780, Epub 01 Nov 1992

    PubMed Central  PubMed  Google Scholar 

  • Dean M, Carrington M, Winkler C et al (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the Ckr5 structural gene. Hemophilia growth and development study, multicenter AIDS cohort study, multicenter hemophilia cohort study, San Francisco city cohort, alive study. Science 273(5283):1856–1862, Epub 27 Sept 1996

    CAS  PubMed  Google Scholar 

  • Deeks SG, Lu J, Hoh J et al (2007) Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 195(3):387–391, Epub 06 Jan 2007

    CAS  PubMed  Google Scholar 

  • Delwart EL, Mosialos G, Gilmore T (1990) Retroviral envelope glycoproteins contain a “leucine zipper”-like repeat. AIDS Res Hum Retroviruses 6(6):703–706, Epub 01 Jun 1990

    CAS  PubMed  Google Scholar 

  • Derdeyn CA, Decker JM, Sfakianos JN et al (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of Gp120. J Virol 74(18):8358–8367, Epub 23 Aug 2000

    PubMed Central  CAS  PubMed  Google Scholar 

  • Donahue DA, Sloan RD, Kuhl BD et al (2010) Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother 54(3):1047–1054

    PubMed Central  CAS  PubMed  Google Scholar 

  • Donzella GA, Schols D, Lin SW et al (1998) Amd3100, a small molecule inhibitor of HIV-1 entry via the Cxcr4 Co-receptor. Nat Med 4(1):72–77, Epub 14 Jan 1998

    CAS  PubMed  Google Scholar 

  • Dorr P, Westby M, Dobbs S et al (2005) Maraviroc (Uk-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor Ccr5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49(11):4721–4732

    PubMed Central  CAS  PubMed  Google Scholar 

  • Eggink D, Berkhout B, Sanders RW (2010) Inhibition of HIV-1 by fusion inhibitors. Curr Pharm Des 16(33):3716–3728, Epub 07 Dec 2010

    CAS  PubMed  Google Scholar 

  • Eggink D, Bontjer I, Langedijk JP et al (2011) Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in Gp41 and is accompanied by a dramatic loss of Gp41 function. J Virol 85(20):10785–10797, Epub 13 Aug 2011

    PubMed Central  CAS  PubMed  Google Scholar 

  • Este JA, Cabrera C, Blanco J et al (1999) Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of Cxcr4. J Virol 73(7):5577–5585, Epub 11 Jun 1999

    PubMed Central  CAS  PubMed  Google Scholar 

  • European AIDS Clinical Society (2011) European AIDS Clinical Society (EACS): Treatment Guidelines Version 6.0

    Google Scholar 

  • Fatkenheuer G, Nelson M, Lazzarin A et al (2008) Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 359(14):1442–1455, Epub 04 Oct 2008

    PubMed  Google Scholar 

  • Fiser A-L, Vincent T, Brieu N et al (2010) High Cd4+ T-cell surface Cxcr4 density as a risk factor for R5 to X4 switch in the course of HIV-1 infection. J Acquir Immune Defic Syndr 55(5):529–535

    CAS  PubMed  Google Scholar 

  • Fleishaker DL, Garcia Meijide JA, Petrov A et al (2012) Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res Ther 14(1):R11, Epub 19 Jan 2012

    PubMed Central  CAS  PubMed  Google Scholar 

  • Freed EO, Martin MA (1995) The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 270(41):23883–23886, Epub 13 Oct 1995

    CAS  PubMed  Google Scholar 

  • Funderburg N, Kalinowska M, Eason J et al (2010) Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with Cd4 cell rises in HIV-infected patients. PLoS One 5:10

    Google Scholar 

  • Gallaher WR, Ball JM, Garry RF et al (1989) A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 5(4):431–440, Epub 01 Aug 1989

    CAS  PubMed  Google Scholar 

  • Garcia-Perez J, Rueda P, Alcami J et al (2011) Allosteric model of maraviroc binding to Cc chemokine receptor 5 (Ccr5). J Biol Chem 286(38):33409–33421, Epub 22 July 2011

    PubMed Central  CAS  PubMed  Google Scholar 

  • Greenberg ML, Cammack N (2004) Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54(2):333–340, Epub 03 July 2004

    CAS  PubMed  Google Scholar 

  • Grinsztejn B, Nguyen BY, Katlama C et al (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (Mk-0518) in treatment-experienced patients with multidrug-resistant virus: a phase Ii randomised controlled trial. Lancet 369(9569):1261–1269, Epub 17 Apr 2007

    CAS  PubMed  Google Scholar 

  • Gulick RM, Su Z, Flexner C et al (2007) Phase 2 study of the safety and efficacy of vicriviroc, a Ccr5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 196(2):304–312, Epub 16 Jun 2007

    CAS  PubMed  Google Scholar 

  • Gulick RM, Lalezari J, Goodrich J et al (2008) Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359(14):1429–1441, Epub 04 Oct 2008

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hanna GJ, Lalezari J, Hellinger JA et al (2011) Antiviral activity, pharmacokinetics, and safety of Bms-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Chemother 55(2):722–728, Epub 17 Nov 2010

    PubMed Central  CAS  PubMed  Google Scholar 

  • Harrison JE, Lynch JB, Sierra LJ et al (2008) Baseline resistance of primary human immunodeficiency virus type 1 strains to the Cxcr4 inhibitor Amd3100. J Virol 82(23):11695–11704, Epub 19 Sept 2008

    PubMed Central  CAS  PubMed  Google Scholar 

  • He Y, Xiao Y, Song H et al (2008) Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 283(17):11126–11134, Epub 28 Feb 2008

    CAS  PubMed  Google Scholar 

  • Hendrix CW, Collier AC, Lederman MM et al (2004) Safety, pharmacokinetics, and antiviral activity of Amd3100, a selective Cxcr4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37(2):1253–1262, Epub 24 Sept 2004

    CAS  PubMed  Google Scholar 

  • Henrich TJ, Tsibris AM, Lewine NR et al (2010) Evolution of Ccr5 antagonist resistance in an HIV-1 subtype C clinical isolate. J Acquir Immune Defic Syndr 55(4):420–427, Epub 22 Sept 2010

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hernandez PA, Gorlin RJ, Lukens JN et al (2003) Mutations in the chemokine receptor gene Cxcr4 are associated with whim syndrome, a combined immunodeficiency disease. Nat Genet 34(1):70–74, Epub 15 Apr 2003

    CAS  PubMed  Google Scholar 

  • Ho HT, Fan L, Nowicka-Sans B et al (2006) Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent Cd4 binding and downstream entry events. J Virol 80(8):4017–4025, Epub 31 Mar 2006

    PubMed Central  CAS  PubMed  Google Scholar 

  • Huang Y, Paxton WA, Wolinsky SM et al (1996) The role of a mutant Ccr5 allele in HIV-1 transmission and disease progression. Nat Med 2(11):1240–1243, Epub 01 Nov 1996

    CAS  PubMed  Google Scholar 

  • Huang CC, Tang M, Zhang MY et al (2005) Structure of a V3-containing HIV-1 Gp120 core. Science 310(5750):1025–1028, Epub 15 Nov 2005

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hütter G, Allers K, Schneider T (2009) The additional use of viral entry inhibitors during autologous hematopoietic stem cell transplantation in patients with non-Hodgkin S Lymphoma and HIV-1 infection. Biol Blood Marrow Transplant 17(4):586–587

    PubMed  Google Scholar 

  • Izumi K, Kodama E, Shimura K et al (2009) Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. J Biol Chem 284(8):4914–4920, Epub 17 Dec 2008

    PubMed Central  CAS  PubMed  Google Scholar 

  • Jacobson JM, Saag MS, Thompson MA et al (2008) Antiviral activity of single-dose Pro 140, a Ccr5 monoclonal antibody, in HIV-infected adults. J Infect Dis 198(9):1345–1352, Epub 06 Sept 2008

    PubMed  Google Scholar 

  • Jacobson JM, Kuritzkes DR, Godofsky E et al (2009) Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly Tnx-355), an anti-Cd4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 53(2):450–457, Epub 19 Nov 2008

    PubMed Central  CAS  PubMed  Google Scholar 

  • Jacobson JM, Thompson MA, Lalezari JP et al (2010) Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous Pro 140, a Ccr5 monoclonal antibody. J Infect Dis 201(10):1481–1487, Epub 10 Apr 2010

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kanbara K, Sato S, Tanuma J et al (2001) Biological and genetic characterization of a human immunodeficiency virus strain resistant to Cxcr4 antagonist T134. AIDS Res Hum Retroviruses 17(7):615–622, Epub 26 May 2001

    CAS  PubMed  Google Scholar 

  • Kilby JM, Hopkins S, Venetta TM et al (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of Gp41-mediated virus entry. Nat Med 4(11):1302–1307, Epub 11 Nov 1998

    CAS  PubMed  Google Scholar 

  • Kilby JM, Lalezari JP, Eron JJ et al (2002) The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of Gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 18(10):685–693, Epub 09 Aug 2002

    CAS  PubMed  Google Scholar 

  • Kindberg E, Mickiene A, Ax C et al (2008) A deletion in the chemokine receptor 5 (Ccr5) gene is associated with tickborne encephalitis. J Infect Dis 197(2):266–269, Epub 09 Jan 2008

    CAS  PubMed  Google Scholar 

  • Kramer VG, Schader SM, Oliveira M et al (2012) Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob Agents Chemother 56(8):4154–4160, Epub 23 May 2012

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kuhmann SE, Pugach P, Kunstman KJ et al (2004) Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule Ccr5 inhibitor. J Virol 78(6):2790–2807, Epub 03 Mar 2004

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kuritzkes DR (2009) HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS 4(2):82–87, Epub 03 Apr 2009

    PubMed Central  PubMed  Google Scholar 

  • Kuritzkes DR, Jacobson J, Powderly WG et al (2004) Antiretroviral activity of the anti-Cd4 monoclonal antibody Tnx-355 in patients infected with HIV type 1. J Infect Dis 189(2):286–291, Epub 15 Jan 2004

    CAS  PubMed  Google Scholar 

  • Kwong PD, Wyatt R, Robinson J et al (1998) Structure of an HIV Gp120 envelope glycoprotein in complex with the Cd4 receptor and a neutralizing human antibody. Nature 393(6686):648–659, Epub 26 Jun 1998

    CAS  PubMed  Google Scholar 

  • Lalezari JP, Henry K, O’Hearn M et al (2003a) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in north and south America. N Engl J Med 348(22):2175–2185

    CAS  PubMed  Google Scholar 

  • Lalezari JP, Eron JJ, Carlson M et al (2003b) A phase Ii clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17(5):691–698, Epub 21 Mar 2003

    CAS  PubMed  Google Scholar 

  • Lalezari J, Thompson M, Kumar P et al (2005) Antiviral activity and safety of 873140, a novel Ccr5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 19(14):1443–1448, Epub 02 Sept 2005

    CAS  PubMed  Google Scholar 

  • Lalezari J, Gathe J, Brinson C et al (2011) Safety, efficacy, and pharmacokinetics of Tbr-652, a Ccr5/Ccr2 antagonist, in HIV-1-infected, treatment-experienced, Ccr5 antagonist-naive subjects. J Acquir Immune Defic Syndr 57(2):118–125, Epub 15 Feb 2011

    CAS  PubMed  Google Scholar 

  • Lazzarin A, Clotet B, Cooper D et al (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348(22):2186–2195, Epub 30 May 2003

    CAS  PubMed  Google Scholar 

  • Leung PH, Chen JH, Wong KH et al (2010) High prevalence of primary enfuvirtide (Enf) resistance-associated mutations in HIV-1-infected patients in Hong Kong. J Clin Virol 47(3):273–275, Epub 02 Feb 2010

    CAS  PubMed  Google Scholar 

  • Lim JK, Louie CY, Glaser C et al (2008) Genetic deficiency of chemokine receptor Ccr5 is a strong risk factor for symptomatic west Nile virus infection: a meta-analysis of 4 cohorts in the Us epidemic. J Infect Dis 197(2):262–265, Epub 09 Jan 2008

    PubMed  Google Scholar 

  • Lin PF, Blair W, Wang T et al (2003) A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits Cd4 receptor binding. Proc Natl Acad Sci U S A 100(19):11013–11018, Epub 22 Aug 2003

    PubMed Central  CAS  PubMed  Google Scholar 

  • Liu R, Paxton WA, Choe S et al (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86(3):367–377, Epub 09 Aug 1996

    CAS  PubMed  Google Scholar 

  • Liu Q, Chen H, Ojode T et al (2012) Whim syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor Cxcr4. Blood 120(1):181–189, Epub 19 May 2012

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ma Q, Jones D, Borghesani PR et al (1998) Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in Cxcr4- and Sdf-1-deficient mice. Proc Natl Acad Sci U S A 95(16):9448–9453, Epub 05 Aug 1998

    PubMed Central  CAS  PubMed  Google Scholar 

  • Makinson A, Reynes J (2009) The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr Opin HIV AIDS 4(2):150–158, Epub 03 Apr 2009

    PubMed  Google Scholar 

  • Marcelin AG, Reynes J, Yerly S et al (2004) Characterization of genotypic determinants in Hr-1 and Hr-2 Gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS 18(9):1340–1342, Epub 15 Sept 2004

    CAS  PubMed  Google Scholar 

  • Marier JF, Trinh M, Pheng LH et al (2011) Pharmacokinetics and pharmacodynamics of Tbr-652, a novel Ccr5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, Ccr5 antagonist-naive patients. Antimicrob Agents Chemother 55(6):2768–2774, Epub 14 Apr 2011

    PubMed Central  CAS  PubMed  Google Scholar 

  • Markowitz M, Nguyen BY, Gotuzzo E et al (2007) Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46(2):125–133, Epub 28 Aug 2007

    CAS  PubMed  Google Scholar 

  • Marozsan AJ, Kuhmann SE, Morgan T et al (2005) Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule Ccr5 inhibitor, Sch-417690 (Sch-D). Virology 338(1):182–199, Epub 07 Jun 2005

    CAS  PubMed  Google Scholar 

  • McDermott DH, Liu Q, Ulrick J et al (2011a) The Cxcr4 antagonist plerixafor corrects panleukopenia in patients with whim syndrome. Blood 118(18):4957–4962, Epub 06 Sept 2011

    PubMed Central  CAS  PubMed  Google Scholar 

  • McDermott DH, Lopez J, Deng F et al (2011b) Amd3100 is a potent antagonist at Cxcr4(R334x), a hyperfunctional mutant chemokine receptor and cause of whim syndrome. J Cell Mol Med 15(10):2071–2081, Epub 13 Nov 2010

    PubMed Central  CAS  PubMed  Google Scholar 

  • McNicholas P, Wei Y, Whitcomb J et al (2010) Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial. J Infect Dis 201(10):1470–1480, Epub 09 Apr 2010

    CAS  PubMed  Google Scholar 

  • McNicholas PM, Mann PA, Wojcik L et al (2011) Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase Ii study (victor-E1). J Acquir Immune Defic Syndr 56(3):222–229, Epub 07 Jan 2011

    CAS  PubMed  Google Scholar 

  • Melby TE, Despirito M, Demasi RA et al (2007) Association between specific enfuvirtide resistance mutations and Cd4 cell response during enfuvirtide-based therapy. AIDS 21(18):2537–2539, Epub 21 Nov 2007

    CAS  PubMed  Google Scholar 

  • Michael NL, Louie LG, Rohrbaugh AL et al (1997) The role of Ccr5 and Ccr2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 3(10):1160–1162, Epub 23 Oct 1997

    CAS  PubMed  Google Scholar 

  • Mills A, Mildvan D, Podzamczer D et al (eds) (2012) Once-daily Maraviroc in combination with Ritonavir-boosted Atazanavir in treatment-NaïVe patients infected with Ccr5-tropic HIV-1 (Study A4001078): 96-Week results. In: IAS 2012, Washington, DC

    Google Scholar 

  • Moulard M, Decroly E (2000) Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochim Biophys Acta 1469(3):121–132, Epub 07 Nov 2000

    CAS  PubMed  Google Scholar 

  • Moyle GJ, Wildfire A, Mandalia S et al (2005) Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 191(6):866–872, Epub 18 Feb 2005

    PubMed  Google Scholar 

  • Moyle G, DeJesus E, Boffito M et al (2009) Proof of activity with Amd11070, an orally bioavailable inhibitor of Cxcr4-tropic HIV type 1. Clin Infect Dis 48(6):798–805, Epub 06 Feb 2009

    CAS  PubMed  Google Scholar 

  • Nagasawa T, Hirota S, Tachibana K et al (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the Cxc chemokine pbsf/Sdf-1. Nature 382(6592):635–638, Epub 15 Aug 1996

    CAS  PubMed  Google Scholar 

  • Nelson M, Arasteh K, Clotet B et al (2005) Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 40(4):404–412, Epub 11 Nov 2005

    CAS  PubMed  Google Scholar 

  • Nettles RE, Schurmann D, Zhu L et al (2012) Pharmacodynamics, safety, and pharmacokinetics of Bms-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis 206(7):1002–1011, Epub 17 Aug 2012

    CAS  PubMed  Google Scholar 

  • Nowicka-Sans B, Gong YF, McAuliffe B et al (2012) In vitro antiviral characteristics of HIV-1 attachment inhibitor Bms-626529, the active component of the prodrug Bms-663068. Antimicrob Agents Chemother 56(7):3498–3507, Epub 02 May 2012

    PubMed Central  CAS  PubMed  Google Scholar 

  • Olson WC, Rabut GE, Nagashima KA et al (1999) Differential inhibition of human immunodeficiency virus type 1 fusion, Gp120 binding, and Cc-chemokine activity by monoclonal antibodies to Ccr5. J Virol 73(5):4145–4155, Epub 10 Apr 1999

    PubMed Central  CAS  PubMed  Google Scholar 

  • Pace CS, Fordyce MW, Franco D et al (2013) Anti-Cd4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr 62(1):1–9, Epub 02 Oct 2012

    CAS  PubMed  Google Scholar 

  • Pastore C, Ramos A, Mosier DE (2004) Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 78(14):7565–7574, Epub 29 Jun 2004

    PubMed Central  CAS  PubMed  Google Scholar 

  • Perez-Olmeda M, Cascajero A, Rastrojo A et al. (eds) (2012) Dynamic of HIV-1 quasi-species during a short exposure to Maraviroc in NaïVe patients using 454 ultra-deep sequencing. In: 19th conference on retroviruses and opportunistic infections, 2012, Seattle

    Google Scholar 

  • Pfaff JM, Wilen CB, Harrison JE et al (2010) HIV-1 resistance to Ccr5 antagonists associated with highly efficient use of Ccr5 and altered tropism on primary Cd4+ T cells. J Virol 1–34

    Google Scholar 

  • Platt EJ, Gomes MM, Kabat D (2012) Kinetic mechanism for HIV-1 neutralization by antibody 2g12 entails reversible glycan binding that slows cell entry. Proc Natl Acad Sci U S A 109(20):7829–7834, Epub 02 May 2012

    PubMed Central  CAS  PubMed  Google Scholar 

  • Pope M, Haase AT (2003) Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 9(7):847–852, Epub 02 July 2003

    CAS  PubMed  Google Scholar 

  • Prahalad S (2006) Negative association between the chemokine receptor Ccr5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun 7(3):264–268, Epub 17 Mar 2006

    PubMed Central  CAS  PubMed  Google Scholar 

  • Putcharoen O, Lee SH, Henrich TJ et al (2012) HIV-1 clinical isolates resistant to Ccr5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J Virol 86(2):1119–1128, Epub 18 Nov 2011

    PubMed Central  CAS  PubMed  Google Scholar 

  • Rappaport J, Cho YY, Hendel H et al (1997) 32 Bp Ccr-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes. Lancet 349(9056):922–923, Epub 29 Mar 1997

    CAS  PubMed  Google Scholar 

  • Ratcliff AN, Shi W, Arts EJ (2013) HIV-1 resistance to maraviroc conferred by a Cd4 binding site mutation in the envelope glycoprotein Gp120. J Virol 87(2):923–934, Epub 09 Nov 2012

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ray N, Blackburn LA, Doms RW (2009) Hr-2 mutations in human immunodeficiency virus type 1 Gp41 restore fusion kinetics delayed by Hr-1 mutations that cause clinical resistance to enfuvirtide. J Virol 83(7):2989–2995, Epub 21 Jan 2009

    PubMed Central  CAS  PubMed  Google Scholar 

  • Recordon-Pinson P, Raymond S, Bellecave P et al (2013) HIV-1 dynamics and coreceptor usage in maraviroc-treated patients with ongoing replication. Antimicrob Agents Chemother 57(2):930–935, Epub 05 Dec 2012

    PubMed Central  CAS  PubMed  Google Scholar 

  • Reeves JD, Lee FH, Miamidian JL et al (2005) Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 79(8):4991–4999, Epub 30 Mar 2005

    PubMed Central  CAS  PubMed  Google Scholar 

  • Regoes RR, Bonhoeffer S (2005) The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 13(6):269–277

    CAS  PubMed  Google Scholar 

  • Reshef R, Luger SM, Hexner EO et al (2012) Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 367(2):135–145, Epub 13 July 2012

    PubMed Central  CAS  PubMed  Google Scholar 

  • Reynes J, Arasteh K, Clotet B et al (2007) Toro: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 21(8):533–543, Epub 23 Aug 2007

    PubMed  Google Scholar 

  • Roche M, Jakobsen M, Sterjovski J et al (2011a) HIV-1 escape from the Ccr5 antagonist maraviroc associated with an altered and less efficient mechanism of Gp120-Ccr5 engagement that attenuates macrophage-tropism. J Virol 85(9):4330–4342. doi:10.1128/JVI.00106-11v1

    PubMed Central  CAS  PubMed  Google Scholar 

  • Roche M, Jakobsen MR, Ellett A et al (2011b) HIV-1 predisposed to acquiring resistance to maraviroc (Mvc) and other Ccr5 antagonists in vitro has an inherent, low-level ability to utilize Mvc-bound Ccr5 for entry. Retrovirology 8:89, Epub 08 Nov 2011

    PubMed Central  CAS  PubMed  Google Scholar 

  • Roche M, Salimi H, Duncan R et al (2013) A common mechanism of clinical HIV-1 resistance to the Ccr5 antagonist maraviroc despite divergent resistance levels and lack of common Gp120 resistance mutations. Retrovirology 10(1):43, Epub 23 Apr 2013

    PubMed Central  CAS  PubMed  Google Scholar 

  • Saag M, Goodrich J, Fatkenheuer G et al (2009) A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 199(11):1638–1647, Epub 13 May 2009

    CAS  PubMed  Google Scholar 

  • Samson M, Libert F, Doranz BJ et al (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the Ccr-5 chemokine receptor gene. Nature 382(6593):722–725, Epub 22 Aug 1996

    CAS  PubMed  Google Scholar 

  • Savkovic B, Symonds G, Murray JM (2012) Stochastic model of in-vivo X4 emergence during HIV infection: implications for the Ccr5 inhibitor maraviroc. PLoS One 7(7):e38755, Epub 07 Aug 2012

    PubMed Central  CAS  PubMed  Google Scholar 

  • Scarlatti G, Tresoldi E, Bjorndal A et al (1997) In vivo evolution of HIV-1 Co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 3(11):1259–1265, Epub 14 Nov 1997

    CAS  PubMed  Google Scholar 

  • Schols D, Este JA, Cabrera C et al (1998) T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope Gp120 but does not show a switch in coreceptor use. J Virol 72(5):4032–4037, Epub 29 Apr 1998

    PubMed Central  CAS  PubMed  Google Scholar 

  • Schooley RT, Merigan TC, Gaut P et al (1990) Recombinant soluble Cd4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-Ii escalating dosage trial. Ann Intern Med 112(4):247–253, Epub 15 Feb 1990

    CAS  PubMed  Google Scholar 

  • Schroder C, Pierson RN 3rd, Nguyen BN et al (2007) Ccr5 blockade modulates inflammation and alloimmunity in primates. J Immunol 179(4):2289–2299, Epub 07 Aug 2007

    PubMed  Google Scholar 

  • Schuitemaker H, Koot M, Kootstra NA et al (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66(3):1354–1360, Epub 01 Mar 1992

    PubMed Central  CAS  PubMed  Google Scholar 

  • Sedaghat AR, Dinoso JB, Shen L et al (2008) Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A 105(12):4832–4837, Epub 26 Mar 2008

    PubMed Central  CAS  PubMed  Google Scholar 

  • Shioda T, Levy JA, Cheng-Mayer C (1991) Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope Gp120 gene. Nature 349(6305):167–169, Epub 10 Jan 1991

    CAS  PubMed  Google Scholar 

  • Shioda T, Levy JA, Cheng-Mayer C (1992) Small amino acid changes in the V3 hypervariable region of Gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 89(20):9434–9438, Epub 15 Oct 1992

    PubMed Central  CAS  PubMed  Google Scholar 

  • Sierra-Madero J, Di Perri G, Wood R et al (2010) Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the merit study. HIV Clin Trials 11(3):125–132, Epub 26 Aug 2010

    CAS  PubMed  Google Scholar 

  • Skerlj RT, Bridger GJ, Kaller A et al (2010) Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem 53(8):3376–3388, Epub 20 Mar 2010

    CAS  PubMed  Google Scholar 

  • Skerlj R, Bridger G, McEachern E et al (2011) Design of novel Cxcr4 antagonists that Are potent inhibitors of T-tropic (X4) HIV-1 replication. Bioorg Med Chem Lett 21(5):1414–1418, Epub 08 Feb 2011

    CAS  PubMed  Google Scholar 

  • Soria A, Cavarelli M, Sala S et al (2008) Unexpected dramatic increase in Cd4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations. J Med Virol 80(6):937–941, Epub 23 Apr 2008

    CAS  PubMed  Google Scholar 

  • Soulie C, Lambert-Niclot S, Fofana DB et al (2013) Frequency of amino acid changes associated with resistance to attachment inhibitor Bms-626529 in R5- and X4-tropic HIV-1 subtype B. J Antimicrob Chemother 68(6):1243–1245, Epub 12 Feb 2013

    CAS  PubMed  Google Scholar 

  • Stone ND, Dunaway SB, Flexner C et al (2007) Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral Amd070, a selective Cxcr4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 51(7):2351–2358, Epub 25 Apr 2007

    PubMed Central  CAS  PubMed  Google Scholar 

  • Sullivan N, Sun Y, Binley J et al (1998) Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble Cd4 and monoclonal antibodies. J Virol 72(8):6332–6338, Epub 11 July 1998

    PubMed Central  CAS  PubMed  Google Scholar 

  • Svicher V, Aquaro S, D’Arrigo R et al (2008) Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in Cd4(+) cell count, despite virological failure. J Infect Dis 197(10):1408–1418, Epub 19 Apr 2008

    CAS  PubMed  Google Scholar 

  • Symons J, van Lelyveld SFL, Hoepelman AIM et al (2011) Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. J Antimicrob Chemother 66(4):890–895

    CAS  PubMed  Google Scholar 

  • Symons J, Deeks S, Hutter G et al (eds) (2012) The cure of the ‘Berlin patient’: why did pre-existing X4-variants not emergence after allogeneic Ccr5-Δ32 Sct? In: AIDS 2012, Washington, DC

    Google Scholar 

  • Tachibana K, Hirota S, Iizasa H et al (1998) The chemokine receptor Cxcr4 is essential for vascularization of the gastrointestinal tract. Nature 393(6685):591–594, Epub 20 Jun 1998

    CAS  PubMed  Google Scholar 

  • Tilton JC, Doms RW (2010) Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 85(1):91–100, Epub 18 Aug 2009

    CAS  PubMed  Google Scholar 

  • Tilton JC, Amrine-Madsen H, Miamidian JL et al (2010) HIV type 1 from a patient with baseline resistance to Ccr5 antagonists uses drug-bound receptor for entry. AIDS Res Hum Retroviruses 26(1):13–24, Epub 09 Jan 2010

    PubMed Central  CAS  PubMed  Google Scholar 

  • Toma J, Weinheimer SP, Stawiski E et al (2011) Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to Cd4 antibody ibalizumab. J Virol 85(8):3872–3880, Epub 04 Feb 2011

    PubMed Central  CAS  PubMed  Google Scholar 

  • Trkola A, Kuhmann SE, Strizki JM et al (2002) HIV-1 escape from a small molecule, Ccr5-specific entry inhibitor does not involve Cxcr4 use. Proc Natl Acad Sci U S A 99(1):395–400, Epub 10 Jan 2002

    PubMed Central  CAS  PubMed  Google Scholar 

  • Tsibris AM, Sagar M, Gulick RM et al (2008) In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 82(16):8210–8214, Epub 23 May 2008

    PubMed Central  CAS  PubMed  Google Scholar 

  • USFDA (2009) Food and Drug Administration: Expanded indication for Selzentry (maraviroc)

    Google Scholar 

  • Westby M, Lewis M, Whitcomb J et al (2006) Emergence of Cxcr4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the Ccr5 antagonist maraviroc is from a pretreatment Cxcr4-using virus reservoir. J Virol 80(10):4909–4920, Epub 28 Apr 2006

    PubMed Central  CAS  PubMed  Google Scholar 

  • Wheeler J, McHale M, Jackson V et al (2007) Assessing theoretical risk and benefit suggested by genetic association studies of Ccr5: experience in a drug development programme for maraviroc. Antivir Ther 12(2):233–245, Epub 17 May 2007

    CAS  PubMed  Google Scholar 

  • Wild C, Greenwell T, Matthews T (1993) A synthetic peptide from HIV-1 Gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 9(11):1051–1053, Epub 01 Nov 1993

    CAS  PubMed  Google Scholar 

  • Wilkin TJ, Su Z, Kuritzkes DR et al (2007) HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a Ccr5 inhibitor: AIDS clinical trial group A5211. Clin Infect Dis 44(4):591–595, Epub 24 Jan 2007

    CAS  PubMed  Google Scholar 

  • Winkler C, Modi W, Smith MW et al (1998) Genetic restriction of AIDS pathogenesis by an Sdf-1 chemokine gene variant. Alive study, hemophilia growth and development study (hgds), multicenter AIDS cohort study (Macs), multicenter hemophilia cohort study (mhcs), San Francisco city cohort (sfcc). Science 279(5349):389–393, Epub 07 Feb 1998

    CAS  PubMed  Google Scholar 

  • Xu L, Pozniak A, Wildfire A et al (2005) Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within Gp41. Antimicrob Agents Chemother 49(3):1113–1119, Epub 25 Feb 2005

    PubMed Central  CAS  PubMed  Google Scholar 

  • Yu X, Yuan L, Huang Y et al (2011) Susceptibility of HIV-1 subtypes B′, Crf07_Bc and Crf01_Ae that are predominantly circulating in china to HIV-1 entry inhibitors. PLoS One 6(3):e17605

    PubMed Central  CAS  PubMed  Google Scholar 

  • Zhang X, Nieforth K, Lang JM et al (2002) Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 72(1):10–19, Epub 02 Aug 2002

    CAS  PubMed  Google Scholar 

  • Zhou N, Fan L, Ho HT et al (2010) Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies. Virology 402(2):256–261, Epub 20 Apr 2010

    CAS  PubMed  Google Scholar 

  • Zhou N, Nowicka-Sans B, Zhang S et al (2011) In vivo patterns of resistance to the HIV attachment inhibitor Bms-488043. Antimicrob Agents Chemother 55(2):729–737, Epub 17 Nov 2010

    PubMed Central  CAS  PubMed  Google Scholar 

  • Zou YR, Kottmann AH, Kuroda M et al (1998) Function of the chemokine receptor Cxcr4 in haematopoiesis and in cerebellar development. Nature 393(6685):595–599, Epub 20 Jun 1998

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental Medicine, McGill University, Montreal, QC, Canada

    Victor G. Kramer

  2. AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, QC, Canada

    Mark A. Wainberg

Authors
  1. Victor G. Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark A. Wainberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victor G. Kramer .

Editor information

Editors and Affiliations

  1. McGill University, Montreal, Québec, Canada

    Matthias Gotte

  2. McGill University, Montreal, Canada

    Albert Berghuis

  3. McGill University, Montreal, Canada

    Greg Matlashewski

  4. McGill University, Montreal, Canada

    Mark Wainberg

  5. McGill University, Montreal, Canada

    Donald Sheppard

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this entry

Cite this entry

Kramer, V.G., Wainberg, M.A. (2014). HIV-1 Entry Inhibitor Resistance. In: Gotte, M., Berghuis, A., Matlashewski, G., Wainberg, M., Sheppard, D. (eds) Handbook of Antimicrobial Resistance. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0667-3_25-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0667-3_25-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Online ISBN: 978-1-4939-0667-3

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation